Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Strategic Projects - Group

Simon Fraser University

$177,500.00

Production of high-quality proteins in plants for treatment of human lysosomal storage diseases

FY 2009-10

Summary
Whole plants and cultured plant cells are potentially one of the most economical systems for large-scale production of recombinant proteins for industrial and pharmaceutical uses. As the demand for biological drugs increases as predicted, efficient production, in terms of cost and volume, will be critical to meet the rising demand. In the near future, some of the current production systems for generating recombinant proteins for therapeutic purposes will need to be replaced by safer, and more cost-efficient, production systems. Mucopolysaccharidosis I (MPS I) and Gaucher disease are inherited lysosomal storage diseases (LSDs). The former is characterized by a deficiency of an enzyme called alpha-L-iduronidase; in severely affected humans this genetic disease leads to death in early childhood because of profound skeletal, cardiac and neurological disturbances. Purified enzyme is an effective means to restore lysosomal enzyme deficiency. Thus, LSDs, that collectively represent over 50 disorders, are amenable to enzyme replacement therapies (ERT). However, the current methods used to commercially produce recombinant lysosomal enzymes for this purpose, most commonly mammalian cell cultures, are prohibitively costly. Because of this, financial support for ERT on affected Canadians is doubtful. We are using plants as hosts to produce human enzymes toward developing more economical treatments for MPS I and Gaucher disease, and to serve as a general platform for plant production of therapeutic proteins. As well as testing the therapeutic efficacy of our plant-derived enzymes, as a long-term goal, we will establish an in vivo plant-based system for assessing the efficacy of pharmacological chaperones and other small molecules as LSD therapies. This project brings together a unique International team of researchers that have expertise in the genetic basis, pathophysiology, and treatment of human LSDs, protein glycosylation within the context of medicinal chemistry, and recombinant protein production in plants.
Program
Strategic Projects - Group
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
350770-2007
Name nom
Kermode, Allison
Department département
Biological Sciences
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2007
Award amount
177500
Program id
STPGP
Program nane en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1044
Committee name en
Strategic Projects Selection Panel - Food and Bioproducts
Committee name fr
Comité de sélection des projets stratégiques - Aliments et bioproduits
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5300
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Molecular biology
Research subject fr
Biologie moléculaire
Partie
3
Nb partie
3
Application title
Production of high-quality proteins in plants for treatment of human lysosomal storage diseases
Keyword
NA
Application summary
Whole plants and cultured plant cells are potentially one of the most economical systems for large-scale production of recombinant proteins for industrial and pharmaceutical uses. As the demand for biological drugs increases as predicted, efficient production, in terms of cost and volume, will be critical to meet the rising demand. In the near future, some of the current production systems for generating recombinant proteins for therapeutic purposes will need to be replaced by safer, and more cost-efficient, production systems. Mucopolysaccharidosis I (MPS I) and Gaucher disease are inherited lysosomal storage diseases (LSDs). The former is characterized by a deficiency of an enzyme called alpha-L-iduronidase; in severely affected humans this genetic disease leads to death in early childhood because of profound skeletal, cardiac and neurological disturbances. Purified enzyme is an effective means to restore lysosomal enzyme deficiency. Thus, LSDs, that collectively represent over 50 disorders, are amenable to enzyme replacement therapies (ERT). However, the current methods used to commercially produce recombinant lysosomal enzymes for this purpose, most commonly mammalian cell cultures, are prohibitively costly. Because of this, financial support for ERT on affected Canadians is doubtful. We are using plants as hosts to produce human enzymes toward developing more economical treatments for MPS I and Gaucher disease, and to serve as a general platform for plant production of therapeutic proteins. As well as testing the therapeutic efficacy of our plant-derived enzymes, as a long-term goal, we will establish an in vivo plant-based system for assessing the efficacy of pharmacological chaperones and other small molecules as LSD therapies. This project brings together a unique International team of researchers that have expertise in the genetic basis, pathophysiology, and treatment of human LSDs, protein glycosylation within the context of medicinal chemistry, and recombinant protein production in plants.
Simon Fraser University - $177,500 Grant (2009-10) | Canada Spends